Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar

Victor L. Serebruany; Seth D. Fortmann; Moo Hyun Kim

doi:10.1159/000440798

Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar

Victor L. Serebruany, Seth D. Fortmann, Moo Hyun Kim

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: In contrast to the vast majority of pharmaceuticals on the market, antiplatelet agents are widely prescribed in a uniform, 'one size fits all' manner, without conventional dose adjustments. However, strong evidence yielded from clinical trials repeatedly suggests that patients with a low body weight (LBW), the elderly and those with renal or hepatic impairment may benefit from reduced doses, while younger, heavier patients, males and diabetics may benefit from a dose escalation. Vorapaxar, a thrombin protease-activated receptor-1 inhibitor, has been tested in the TRA2P and TRACER clinical trials, but its efficacy and safety in patients with a LBW is unclear. Objective: To determine the impact of LBW on primary end point rates (PER) and bleeding risk after vorapaxar, as yielded from the TRA2P and TRACER secondary FDA review. Results: The LBW (

Original language	English (US)
Pages (from-to)	69-72
Number of pages	4
Journal	Cardiology
Volume	133
Issue number	2
DOIs	https://doi.org/10.1159/000440798
State	Published - Jan 1 2016

Keywords

Bleeding
Body weight
Dose adjustment
Vorapaxar

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1159/000440798

Cite this

@article{2c387c3b655a4644b70202263b7670b5,

title = "Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar",

abstract = "Background: In contrast to the vast majority of pharmaceuticals on the market, antiplatelet agents are widely prescribed in a uniform, 'one size fits all' manner, without conventional dose adjustments. However, strong evidence yielded from clinical trials repeatedly suggests that patients with a low body weight (LBW), the elderly and those with renal or hepatic impairment may benefit from reduced doses, while younger, heavier patients, males and diabetics may benefit from a dose escalation. Vorapaxar, a thrombin protease-activated receptor-1 inhibitor, has been tested in the TRA2P and TRACER clinical trials, but its efficacy and safety in patients with a LBW is unclear. Objective: To determine the impact of LBW on primary end point rates (PER) and bleeding risk after vorapaxar, as yielded from the TRA2P and TRACER secondary FDA review. Results: The LBW (",

keywords = "Bleeding, Body weight, Dose adjustment, Vorapaxar",

author = "Serebruany, {Victor L.} and Fortmann, {Seth D.} and {Hyun Kim}, Moo",

year = "2016",

month = jan,

day = "1",

doi = "10.1159/000440798",

language = "English (US)",

volume = "133",

pages = "69--72",

journal = "Cardiology",

issn = "0008-6312",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar

AU - Serebruany, Victor L.

AU - Fortmann, Seth D.

AU - Hyun Kim, Moo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: In contrast to the vast majority of pharmaceuticals on the market, antiplatelet agents are widely prescribed in a uniform, 'one size fits all' manner, without conventional dose adjustments. However, strong evidence yielded from clinical trials repeatedly suggests that patients with a low body weight (LBW), the elderly and those with renal or hepatic impairment may benefit from reduced doses, while younger, heavier patients, males and diabetics may benefit from a dose escalation. Vorapaxar, a thrombin protease-activated receptor-1 inhibitor, has been tested in the TRA2P and TRACER clinical trials, but its efficacy and safety in patients with a LBW is unclear. Objective: To determine the impact of LBW on primary end point rates (PER) and bleeding risk after vorapaxar, as yielded from the TRA2P and TRACER secondary FDA review. Results: The LBW (

AB - Background: In contrast to the vast majority of pharmaceuticals on the market, antiplatelet agents are widely prescribed in a uniform, 'one size fits all' manner, without conventional dose adjustments. However, strong evidence yielded from clinical trials repeatedly suggests that patients with a low body weight (LBW), the elderly and those with renal or hepatic impairment may benefit from reduced doses, while younger, heavier patients, males and diabetics may benefit from a dose escalation. Vorapaxar, a thrombin protease-activated receptor-1 inhibitor, has been tested in the TRA2P and TRACER clinical trials, but its efficacy and safety in patients with a LBW is unclear. Objective: To determine the impact of LBW on primary end point rates (PER) and bleeding risk after vorapaxar, as yielded from the TRA2P and TRACER secondary FDA review. Results: The LBW (

KW - Bleeding

KW - Body weight

KW - Dose adjustment

KW - Vorapaxar

UR - http://www.scopus.com/inward/record.url?scp=84955664691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955664691&partnerID=8YFLogxK

U2 - 10.1159/000440798

DO - 10.1159/000440798

M3 - Article

C2 - 26488178

AN - SCOPUS:84955664691

SN - 0008-6312

VL - 133

SP - 69

EP - 72

JO - Cardiology

JF - Cardiology

IS - 2

ER -

Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? the Example of Vorapaxar

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this